Kangji Medical reports revenue growth despite profit dip in first half of 2025

Kangji Medical Holdings Limited reported an 8.3% increase in revenue, reaching RMB496.6 million for the six months ended June 30, 2025, up from RMB458.4 million in the corresponding period of 2024. This growth was primarily driven by a 10.3% increase in disposable product sales, which accounted for 90.9% of total revenue. Overseas market revenue also grew by 27.7% to RMB51.4 million.

Despite the revenue growth, the company's net profit attributable to owners of the parent decreased by 7.0%, from RMB285.8 million in 2024 to RMB265.8 million in 2025. This decline was attributed to a decrease in other income and gains, alongside an increased share of loss from Hangzhou Kangji Wiseking Medical Robot Co., Ltd. Non-HKFRS adjusted net profit also saw an 18.5% decrease to RMB224.1 million.

The Group's gross profit rose by 8.1% to RMB392.4 million, maintaining a stable gross profit margin of 79.0%. Income tax expenses increased by 13.6% to RMB59.1 million. As of June 30, 2025, the Group's cash and cash equivalents stood at RMB1,707.2 million, and the gearing ratio was 3.9%. No interim dividend was recommended for the period.